Barbara Pistilli

ScholarGPS® ID: 66810199595056

Affiliation

Institut Gustave Roussy, France

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

134

Predicted Citations

3,393

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Long road towards effective HER3 targeting in breast cancer (journal article) Papa, Francesca \| Grinda, Thomas \| Rassy, Elie \| Cheickh-Hussin, Rasha \| Ribeiro, Joana \| Antonuzzo, Lorenzo \| Pistilli, Barbara Cancer Treatment Reviews, volume 129 (2024). 10.1016/j.ctrv.2024.102786 Cite \| Source
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools (journal article) Rassy, Elie \| Benvenuti, Chiara \| Akla, Sarra \| Di Meglio, Antonio \| Martin, Elise \| Havas, Julie \| Rieutord, André \| Combarel, David \| Fasse, Léonor \| Scotté, Florian \| ... \| Pistilli, Barbara npj Breast Cancer, volume 10, issue 1 (2024). 10.1038/s41523-024-00655-1 Cite \| Source
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. (journal article) Planchard, David \| Cozic, Nathalie \| Wislez, Marie \| Chouaid, Christos \| Curcio, Hubert \| Cousin, Sophie \| Mascaux, Celine \| Cadranel, Jacques \| Geier, Margaux \| Ghigna, Maria Rosa \| ... \| Pistilli, Barbara Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 8501-8501 (2024). 10.1200/JCO.2024.42.16_suppl.8501 Cited by (1) \| Cite \| Source
Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI. (journal article) Lapidari, Pietro \| Lustberg, Maryam B. \| Havas, Julie \| Pagliuca, Martina \| Franzoi, Maria Alice B \| Menvielle, Gwenn \| Pistilli, Barbara \| Jouannaud, Christelle \| Sauterey, Baptiste \| Tredan, Olivier \| ... \| Di Meglio, Antonio Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 12122-12122 (2024). 10.1200/JCO.2024.42.16_suppl.12122 Cite \| Source
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors. (journal article) Pistilli, Barbara \| Bellet, Meritxell \| Del Mastro, Lucia \| McArthur, Heather L. \| Meisel, Jane Lowe \| Schmid, Peter \| Sohn, Joohyuk \| De Kermadec, Elisabeth \| Wei, Rachel \| Chan, Arlene Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS1135-TPS1135 (2024). 10.1200/JCO.2024.42.16_suppl.TPS1135 Cite \| Source
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxt (journal article) Pegram, Mark D. \| Calfa, Carmen \| Chen, Christopher \| Cortés Salgado, Alfonso \| Heeke, Arielle Lutterman \| Kang, Irene \| Pistilli, Barbara \| Pohlmann, Paula R \| Rugo, Hope S. \| Saura, Cristina \| ... \| Drago, Joshua Z. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS1121-TPS1121 (2024). 10.1200/JCO.2024.42.16_suppl.TPS1121 Cite \| Source
113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC) (journal article) Barrios, C.H. \| Harbeck, N. \| Hortobagyi, G.N. \| O'Shaughnessy, J. \| Huang, C-S. \| Jimenez, M. Martin \| Juric, D. \| Pistilli, B. \| Xu, B. \| De Laurentiis, M. \| ... \| Rugo, H.S. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.103101 Cite \| Source
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicity (journal article) Benvenuti, C. \| Viansone, A.A. \| Jacobs, F. \| Grinda, T. \| Zeghondy, J.Z. \| Gaudio, M. \| Clapis, L. \| Gerosa, R. \| Canzian, J. \| Poisson, C. \| ... \| De Sanctis, R. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.103239 Cited by (1) \| Cite \| Source
142P Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early-stage triple-negative breast cancer (eTNBC) (journal article) Daverio, A.L. \| Giugliano, F. \| Douglas, J.R. Dixon \| Rached, L.W. \| Laparra, A. \| Sakkal, M. \| Bousrih, C. \| Viansone, A.A. \| Delaloge, S. \| Pistilli, B. \| ... \| Henry, T. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.103129 Cite \| Source
132P Clinico-pathological characteristics, treatments and survival outcomes of patients with high-risk hormone receptor positive early breast cancer (HR+ BC) in French real-world (RW) setting: A study from CANTO cohort (journal article) Giugliano, F. \| Bertaut, A. \| Blanc, J. \| Martin, A-L. \| Gaudin, C. \| Fournier, M. \| Kieffer, A. \| Sauterey, B. \| Levy, C. \| Campone, M. \| ... \| Rassy, E. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.103119 Cite \| Source
52P Comparing the genomic landscape of de novo vs recurrent metastatic breast cancer by ctDNA and tissue profiling (journal article) Giugliano, F. \| Douglas, J.R. Dixon \| Dien, A. Tran \| Pagliuca, M. \| Minot, L. \| Rouleau, E. \| Bayle, A. \| Curigliano, G. \| Verret, B. \| Viansone, A.A. \| ... \| Mourato, J.T.L. Ribeiro ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.103059 Cite \| Source
Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy? (journal article) Benvenuti, C. \| Laot, L. \| Grinda, T. \| Lambertini, M. \| Pistilli, B. \| Grynberg, M. ESMO Open, volume 9, issue 2, pages 102228- (2024). 10.1016/j.esmoop.2023.102228 Cited by (2) \| Cite \| Source
Response to Sorscher (journal article) Balazard, Félix \| Bertaut, Aurélie \| Vaz-Luis, Ines \| Pistilli, Barbara JNCI: Journal of the National Cancer Institute, volume 116, issue 1, pages 174-174 (2024). 10.1093/jnci/djad234 Cite \| Source
Telehealth in breast cancer following the coronavirus disease 2019 pandemic (journal article) Zeghondy, Jean \| Rassy, Elie \| Lapidari, Pietro \| Eid, Roland \| Pistilli, Barbara Exploration of Targeted Anti-tumor Therapy, volume 4, issue 6, pages 1249-1259 (2023). 10.37349/etat.2023.00195 Cite \| Source
Optimizing the potential of antibody–drug conjugates in oncology (journal article) Mosele, F. \| Montagnac, G. \| Pistilli, B. \| André, F. Annals of Oncology, volume 34, issue 11, pages 964-967 (2023). 10.1016/j.annonc.2023.08.020 Cited by (1) \| Cite \| Source
Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer (journal article) Giudici, Fabiola \| Pistilli, Barbara \| Vaz-Luis, Ines \| Karimi, Maryam \| Delaloge, Suzette \| Bachelot, Thomas \| Michiels, Stefan \| Bardet, Aurelie British Journal of Cancer, volume 129, issue 9, pages 1516-1523 (2023). 10.1038/s41416-023-02420-w Cite \| Source
Mise en place et évaluation de la télésurveillance à l’Institut Gustave-Roussy (journal article) Fanton d’Andon, Juliette \| Cocq, Ariane \| Gourhant, Mélanie \| Morichau Beauchant, Pierre \| Ferreira, Arlindo \| Pagliuca, Martina \| Scotte, Florian \| Di Palma, Mario \| Abbas Maya, Me \| Duarte Luis, Inès Vas \| ... \| Ribeiro, Joana Bulletin Infirmier du Cancer, volume 23, issue 3, pages 126-129 (2023). 10.1684/bic.2023.251 Cite \| Source
Long-term longitudinal patterns of patient-reported quality of life (QOL) after breast cancer (BC) to inform the implementation of personalized pathways of care. (journal article) Franzoi, Maria Alice B \| Di Meglio, Antonio \| Havas, Julie \| Pistilli, Barbara \| Menvielle, Gwenn \| Jouannaud, Christelle \| Fournier, Marion \| Vanlemmens, Laurence \| Dhaini Merimeche, Asma \| Cottu, Paul-Henri \| ... \| Luis, Ines Maria Vaz Duarte Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 12081-12081 (2023). 10.1200/JCO.2023.41.16_suppl.12081 Cite \| Source
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1). (journal article) Hurvitz, Sara A. \| Andre, Fabrice \| Cristofanilli, Massimo \| Curigliano, Giuseppe \| Giordano, Antonio \| Han, Hyo S. \| Martin, Miguel \| Pistilli, Barbara \| Rugo, Hope S. \| Wesolowski, Robert \| ... \| Loibl, Sibylle Journal of Clinical Oncology, volume 41, issue 16_suppl, pages TPS1118-TPS1118 (2023). 10.1200/JCO.2023.41.16_suppl.TPS1118 Cited by (4) \| Cite \| Source
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead (journal article) Grinda, Thomas \| Rassy, Elie \| Pistilli, Barbara Current Treatment Options in Oncology, volume 24, issue 5, pages 442-465 (2023). 10.1007/s11864-023-01072-5 Cited by (7) \| Cite \| Source